Collegium Pharmaceutical (COLL) Q2 2024 earnings summary

Executive summary

• Q2 2024 net product revenue reached $145.3 million, up 7% year-over-year, with record Belbuca revenue of $52.2 million, up 21% year-over-year, and strong performance from Xtampza ER; Nucynta franchise faced some revenue pressure.

• GAAP net income for Q2 2024 was $19.6 million, a 51% increase year-over-year; adjusted EBITDA was $96.0 million, up 12% year-over-year, reflecting improved operational efficiency.

• Announced $525 million all-cash acquisition of Ironshore Therapeutics, including Jornay PM for ADHD, expected to close in Q3 2024 and be immediately accretive to adjusted EBITDA, diversifying the portfolio and supporting future growth.

• Executed capital deployment strategy, including debt refinancing, $35 million in share repurchases, and redemption of $26.4 million in convertible notes.

• Reaffirmed 2024 guidance for current business, excluding Ironshore impact.

Financial highlights

• Q2 2024 net product revenues were $145.3 million, up from $135.5 million in Q2 2023; Belbuca net revenue hit a record $52.2 million, up 21% year-over-year; Xtampza ER net revenue was $44.6 million, up 8% year-over-year.

• Nucynta franchise net revenue was $44.5 million, down 6% year-over-year.

• GAAP net income was $19.6 million ($0.52 diluted EPS), up from $13.0 million in Q2 2023; adjusted net income was $64.0 million ($1.62 adjusted EPS).

• Adjusted EBITDA for Q2 2024 was $96.0 million, up from $85.8 million in Q2 2023; gross profit was $90.8 million, up from $73.8 million.

• Cash, cash equivalents, and marketable securities at quarter-end were $271.6 million.

Outlook and guidance

• Reaffirmed 2024 guidance: net product revenues of $580–$595 million, adjusted EBITDA of $380–$395 million, and adjusted operating expenses of $120–$125 million; guidance excludes Ironshore impact.

• BELBUCA growth expected from prescription increases; XTAMPZA ER growth from gross to net improvement.

• NUCYNTA franchise to face pressure in 2024, with stability expected in 2025.

• JORNAY PM expected to generate over $100 million in 2024 net revenue; updated guidance for combined business to follow acquisition close.

• Management expects cash and equivalents plus operating cash flows to fund expenses, debt service, and capital needs for the foreseeable future.